Martínez-Mier G, Ávila-Pardo SF, Soto-Miranda E, Méndez-López MT, Budar-Fernández LF

Language: Spanish
References: 8
Page: 17-21
PDF size: 283.55 Kb.

ABSTRACT

Introduction: Induction therapy reduces the frequency of acute rejection and delayed graft function in renal transplantation. Basiliximab and thymoglobulin are most commonly used agents for induction. Methods: Retrospective study of two transplant centers in Veracruz Mexico with deceased donor renal transplantation patients since 2009. Parameters of the donor and recipient were recorded. Efficacy and safety outcomes such as primary graft failure, delayed graft function, acute rejection episodes, hospitalizations during the first year and graft and patient survival were examined. Results: 64 patients receiving a deceased donor kidney transplant (basiliximab, n = 40 and thymoglobulin, n = 24) were studied. Patients who used thymoglobulin had more time on dialysis (111 months) and lower BMI (21.9 kg/m²) patients who received basiliximab (23.9 months, 23.9 kg/m²) (p ‹ 0.05). The rate of delayed graft function, acute rejection and hospitalizations were not significantly different in patients induced with basiliximab or thymoglobulin as both the graft and the patient survival. Conclusion: Our study did not obtain significant differences in rejection episodes, delayed graft function and graft and patient survival using thymoglobulin or basiliximab as induction therapy from 2009 to date.

REFERENCES

1. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, Leichtman AB. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006; 6 (5 Pt 2): 1111-1131.

2. Kidney Disease Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 (Suppl 3): S1-155.

3. Rao PS, Ojo S,A. The Alphabet soup of kidney transplantation: SCD, ECD, DCD—fundamentals for the practicing nephrologist. Clin J Am Soc Nephrol. 2009; 4 (11): 1827-1831.

4. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002; 2 (1): 48-56.

5. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant
patients receiving mycophenolate mofetil and steroids. Transplantation. 2004; 78 (4): 584-590.

6. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Eng J Med. 2006; 355 (19): 1967-1977.

7. Webster AC, Playford EG, Higgins G et al. Interleukin-2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized controlled trials. Transplantation. 2004; 77 (2): 166-176.

8. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010; (1): CD003897. doi: 10.1002/14651858.CD003897.pub3.